TALWIN NX
LOE ApproachingNDAORALTABLETPriority Review
Approved
Dec 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TALWIN NX is an oral tablet small-molecule analgesic approved in 1982 by Sanofi. The product's exact mechanism of action and therapeutic indications are not specified in available data. This is a legacy pain management product in the mature phase of its commercial lifecycle.
LOE Approaching
Moderate competitive pressure (30% index) suggests TALWIN NX faces erosion; commercial teams are likely focused on retention rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
No current job openings are linked to TALWIN NX, reflecting its mature lifecycle stage and limited growth trajectory. Roles on this product involve managing decline, supporting existing patient populations, and ensuring compliance rather than launching or expanding market presence.
Brand ManagerField Sales Representative
Worked on TALWIN NX at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.